Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis

ClinicalTrials.gov ID: NCT00987389

Public ClinicalTrials.gov record NCT00987389. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 26, 2026, 11:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether plasma exchange as well as immunosuppressive therapy are effective in reducing death and end-stage renal disease (ESRD). The trial will also study whether a reduced cumulative dosing regimen of glucocorticoids is as effective as a standard disease regimen. The FDA-OOPD is one of the funding sources for this study.

Study identification

NCT ID: NCT00987389
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: University of Pennsylvania; Other
Enrollment: 704 participants

Conditions and interventions

Conditions

Interventions

Procedure · Other · Drug

Eligibility (public fields only)

Age range: 15 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2010 (Actual)
Primary completion: Aug 2017 (Actual)
Completion: Aug 2017 (Actual)
Last update posted: May 26, 2020

2010 – 2017

United States locations

U.S. sites: 9
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
Cedars-Sinai Medical Center	Los Angeles	California	90048	—
Boston University School of Medicine	Boston	Massachusetts	02118	—
Mayo Clinic	Rochester	Minnesota	55905	—
Washington University School of Medicine	St Louis	Missouri	—	—
University of North Carolina	Chapel Hill	North Carolina	27599	—
Cleveland Clinic	Cleveland	Ohio	44195	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
University of Pittsburgh	Pittsburgh	Pennsylvania	15213	—
University of Virginia	Charlottesville	Virginia	22904	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00987389, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 26, 2020 · Synced Oct 26, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00987389 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →